The purpose of this proposal is to synthesize various analogues of alkyl-lysophospholipids (ALPs) to support two previously funded studies on their biochemistry and pharmacology. the two funded studies (CA-41314 and CA-43297) are designed to evaluate their potential for therapeutic application. The preliminary in vitro data that contributed to the funding of these grants was obtained on small amounts of ALP analogues that were synthesized utilizing funds from other sources. Funding now is requested to scale up the synthesis of preliminary analogues with promising in vitro activity for in vivo evaluation and to expand the preliminary structure-activity relationship study to determine which specific chemical functional groups or combination of groups contribute to the antineoplastic activity of these alkylglycerolipids. Funding of this proposal, in conjunction with our previously established collaboration with researchers at the Bowman Gray School of Medicine lipid biochemistry department, will provide a comprehensive, integrated program to design, synthesize and evaluate ALP analogues for a specific tumor-inhibitory properties. ALPs may be directly cytotoxic to tumor cells or may function as biological response modifiers, or may exhibit both effects. Several possible mechanisms have been proposed to account for the antineoplastic activity of ALPs: direct cytotoxic or cytostatic action, malignant cell differentiation and/or macrophage activation. These effects are believed to be mediated by an interaction between the compounds and the membrane. However, little effort has been made to relate activity to specific portions of the ALP molecule. Since the majority of ALPs expressing antitumor activity to date are dialkyl glycerophosphocholines, it appears advantageous to have non- hydrolyzable moieties at the sn-1 and sn-2 positions of the lipid. The analogues synthesized and tested in this study will indicate what portions of the ALP molecule are necessary for antineoplastic activity and which functional groups will enhance the tumor-inhibitory properties of the ALP molecule. Promising analogues will be more intensively investigated to optimize their antineoplastic activity while minimizing undesirable anaphylactic effects. Analogues with high radiospecific activity will be synthesized to follow their metabolism and aid in the elucidation of the mechanism of action of the ALP molecule.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA042216-03
Application #
3183191
Study Section
Experimental Therapeutics Subcommittee 1 (ET)
Project Start
1988-02-01
Project End
1991-07-31
Budget Start
1990-02-01
Budget End
1991-07-31
Support Year
3
Fiscal Year
1990
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
Schools of Pharmacy
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Kurmasheva, Raushan T; Kurmashev, Dias; Reynolds, C Patrick et al. (2018) Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 65:
Jones, Luke; Richmond, Jennifer; Evans, Kathryn et al. (2017) Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL. Clin Cancer Res 23:3744-3755
Kurmasheva, Raushan T; Gorlick, Richard; Kolb, E Anders et al. (2017) Initial testing of VS-4718, a novel inhibitor of focal adhesion kinase (FAK), against pediatric tumor models by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 64:
He, Zhengfu; Hu, Xing; Liu, Weijin et al. (2017) P53 suppresses ribonucleotide reductase via inhibiting mTORC1. Oncotarget 8:41422-41431
Lock, Richard; Carol, Hernan; Maris, John M et al. (2017) Initial testing (stage 1) of the curaxin CBL0137 by the pediatric preclinical testing program. Pediatr Blood Cancer 64:
Kurmasheva, Raushan T; Sammons, Melissa; Favours, Edward et al. (2017) Initial testing (stage 1) of tazemetostat (EPZ-6438), a novel EZH2 inhibitor, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 64:
Zhou, Xinhui; Liu, Weijin; Hu, Xing et al. (2017) Regulation of CHK1 by mTOR contributes to the evasion of DNA damage barrier of cancer cells. Sci Rep 7:1535
Murphy, Brendan; Yin, Han; Maris, John M et al. (2016) Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis. Cancer Res 76:5798-5809
Richmond, Jennifer; Robbins, Alissa; Evans, Kathryn et al. (2016) Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant. Cancer Res 76:4579-91
Attiyeh, Edward F; Maris, John M; Lock, Richard et al. (2016) Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. Pediatr Blood Cancer 63:276-86

Showing the most recent 10 out of 102 publications